Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cartesian Therapeutics Inc (RNAC)

Cartesian Therapeutics Inc (RNAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 175,787
  • Shares Outstanding, K 26,004
  • Annual Sales, $ 38,910 K
  • Annual Income, $ -77,420 K
  • EBIT $ -84 M
  • EBITDA $ -83 M
  • 60-Month Beta 0.36
  • Price/Sales 4.30
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 350.62% (+22.92%)
  • Historical Volatility 84.34%
  • IV Percentile 80%
  • IV Rank 52.43%
  • IV High 655.45% on 12/17/25
  • IV Low 14.64% on 09/08/25
  • Expected Move (DTE 21) 1.06 (15.72%)
  • Put/Call Vol Ratio 55.00
  • Today's Volume 112
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 1,078
  • Open Int (30-Day) 1,244
  • Expected Range 5.70 to 7.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.82
  • Number of Estimates 5
  • High Estimate -0.76
  • Low Estimate -0.91
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.40 +5.63%
on 12/23/25
9.23 -26.76%
on 12/15/25
-0.67 (-9.02%)
since 11/24/25
3-Month
5.98 +13.04%
on 11/06/25
10.49 -35.54%
on 09/30/25
-3.31 (-32.87%)
since 09/24/25
52-Week
5.98 +13.04%
on 11/06/25
20.12 -66.40%
on 01/16/25
-11.71 (-63.40%)
since 12/24/24

Most Recent Stories

More News
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3)  Disease remission reported as DORIS response seen in...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year ...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors

FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Appoints New Chief Accounting Officer

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cartesian...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2...

RNAC : 6.76 (+5.13%)
Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 6.76 (+5.13%)

Business Summary

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with...

See More

Key Turning Points

3rd Resistance Point 7.34
2nd Resistance Point 7.09
1st Resistance Point 6.92
Last Price 6.76
1st Support Level 6.50
2nd Support Level 6.25
3rd Support Level 6.08

See More

52-Week High 20.12
Fibonacci 61.8% 14.72
Fibonacci 50% 13.05
Fibonacci 38.2% 11.38
Last Price 6.76
52-Week Low 5.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar